Stocks
GlaxoSmithKline (GSK) EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA, £ | ? | 6 485 000 000 | 8 601 000 000 | 9 083 000 000 | 6 668 000 000 | 10 402 000 000 | 11 271 684 805 | ||
| Changes by years, y/y, % | -20% | +33% | +6% | -27% | +56% | +5.2% | |||
GlaxoSmithKline. EBITDA US GAAP, £
GlaxoSmithKline. EBITDA US GAAP, changes, %
GlaxoSmithKline. EBITDA US GAAP, sum by quarters, £
GlaxoSmithKline (GSK) EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA, £ | ? | 3 230 000 000 | 3 361 000 000 | 1 906 684 805 | 1 906 684 805 | 2 774 000 000 | 11 271 684 805 | |
| Changes by years, y/y, % | +40% | +187% | +70% | +70% | -10% | |||
| Changes by quarters, q/q, % | +4% | +4% | -43% | 0% | +45% | |||
